Breaking Down Sichuan Huiyu Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Sichuan Huiyu Pharmaceutical (688553.SS) is a bargain or a risk? In the quarter ending September 30, 2025 the company reported revenue of 288.63 million CNY (a 9.70% quarter-on-quarter decline), with trailing twelve‑month revenue at 984.29 million CNY (down 12.10% year-over-year) after a 2024 annual revenue rebound to 1.09 billion CNY (+18.05% vs. 2023); yet profitability slipped into a first-half 2025 net loss of 80.72 million CNY (versus net income of 65.21 million CNY a year earlier) and basic loss per share of 0.19 CNY (from EPS 0.15 CNY), producing a TTM EPS of 0.11 CNY, a P/E of 168.00 and a P/S of 7.77; balance sheet trends show improved leverage with net debt-to-equity down to 29.1% from 131.8% in 2019, more cash than total debt, total assets up 2.92% in Q1 2025, revenue per employee about 712,220 CNY across 1,382 staff, market capitalizations reported at 8.81 billion CNY (Oct 17, 2025) and 7.65 billion CNY (Dec 18, 2025) with an enterprise value of 6.72 billion CNY, while margins and returns remain modest (TTM net profit margin ~4.8%, ROE 1.1%) even as analysts model a potential 12% annual revenue growth over the next five years-read on to see how these figures translate into investment implications.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Revenue Analysis

• Quarter (Q3 2025): 288.63 million CNY (-9.70% QoQ)
• TTM: 984.29 million CNY (-12.10% YoY)
• FY 2024: 1.09 billion CNY (+18.05% YoY vs. 2023)
• Employees: 1,382; revenue per employee ≈ 712,220 CNY
• Market capitalization (Dec 18, 2025): 7.65 billion CNY; P/S = 7.77

• Decline in both domestic and international sales in 2025 reduced quarterly and TTM revenue.
• FY 2024 growth indicates prior recovery or product mix improvements that were not sustained into 2025.
• High P/S (7.77) versus peers suggests market is pricing in growth or premium margins despite recent revenue contraction.
• Revenue per employee (~712k CNY) provides a productivity benchmark for operational comparisons.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Profitability Metrics

• Net profit (1H2025): net loss of 80.72 million CNY versus net income of 65.21 million CNY in 1H2024.
• Basic loss per share (continuing operations, 1H2025): -0.19 CNY; 1H2024 EPS: 0.15 CNY.
• Trailing twelve-month (TTM) EPS: 0.11 CNY, implying substantially compressed earnings relative to historical levels.
• TTM net profit margin: ~4.8%, reflecting margin contraction.
• Return on equity (ROE, most recent): 1.1%, down from prior-year levels.
• Price-to-earnings (P/E, using TTM EPS): 168.00, indicating a high valuation relative to current earnings.
• Forward P/E: not available - limited visible analyst earnings projections.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Debt vs. Equity Structure

Key balance-sheet shifts and valuation context for Sichuan Huiyu Pharmaceutical Co., Ltd. through late 2024-2025:

• Net debt-to-equity: 29.1% (late 2024), down from 131.8% in 2019 - substantial deleveraging over five years.
• Reported debt-to-equity ratio: increased from ~6% to ~10% in recent years - modest rise in gross leverage.
• Liquidity position: cash on hand exceeds total debt - indicates a net cash stance.
• Market metrics (as of 2025-10-17): market capitalization 8.81 billion CNY; enterprise value 6.72 billion CNY; price-to-sales (P/S) ratio 7.77.
• Balance-sheet growth: total assets +2.92% in Q1 2025 - steady expansion of asset base.

Investor implications and areas to watch:

• Improved net debt-to-equity (29.1%) signals stronger capital structure vs. 2019's highly leveraged position (131.8%).
• Modest rise in gross debt-to-equity (6% → 10%) suggests some additional borrowing but remains low in absolute terms.
• Net cash position (cash > debt) reduces refinancing and interest-rate risk; supports operational flexibility and potential M&A or buybacks.
• Valuation context: P/S at 7.77 with market cap 8.81B CNY and EV 6.72B CNY - investors are paying a premium relative to sales; assess growth trajectory to justify multiple.
• Asset growth of 2.92% in Q1 2025 indicates continued, if modest, expansion of the asset base to support revenue growth.

For a deeper look at ownership, shareholder trends and buying dynamics, see Exploring Sichuan Huiyu Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Liquidity and Solvency

Key short‑term liquidity metrics for Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) are limited in public disclosures, while select profitability and balance‑sheet trends are available and relevant for solvency assessment.

• Current ratio: not publicly disclosed.
• Quick ratio: not publicly disclosed.
• Cash flow from operations (H1 2025): not specified in available sources.

Given limited disclosure on immediate liquidity metrics, investors should weigh the available profitability indicators and asset growth alongside qualitative factors (debt structure, receivables/inventory composition, and covenant terms) when assessing solvency risk. For broader context on shareholder composition and investor interest, see: Exploring Sichuan Huiyu Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Valuation Analysis

Key valuation metrics and recent balance-sheet movement frame investor expectations for Sichuan Huiyu Pharmaceutical. The figures below capture market pricing, profitability margins and balance-sheet trends as of the latest available data.

• P/E = 168.00 implies the market is pricing substantial future growth or demonstrates high momentum/speculation relative to current earnings.
• Forward P/E not available signals limited sell-side earnings forecasts or coverage gaps, increasing reliance on company guidance and primary disclosure.
• P/S of 7.77 shows investors are paying a premium relative to revenue; useful when earnings are volatile or depressed.
• EV (6.72bn) vs. Market Cap (8.81bn) indicates net cash or debt dynamics should be reviewed - EV lower than market cap can reflect a net cash position.

Quick profitability and scale context with the most relevant ratios:

• Investors should pair these metrics with cashflow analysis, debt levels, R&D pipeline valuation and peer multiples to assess whether the premium is justified.
• Limited forward estimates increase the importance of tracking upcoming quarterly results and management commentary for earnings trajectory clarity.

Reference: Mission Statement, Vision, & Core Values (2026) of Sichuan Huiyu Pharmaceutical Co., Ltd.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Risk Factors

• Regulatory and compliance risk: subject to NMPA drug approvals, GMP inspections, quality-control mandates, and price controls that can delay product launches or trigger remediation costs.
• Competitive risk: faces larger domestic and international pharmaceutical companies in therapeutic segments, which may compress pricing power and market share.
• Earnings volatility: revenue and margins can fluctuate with regulatory changes, tender outcomes, and competitive pricing decisions.
• Supply-chain risk: dependence on third-party suppliers for API and excipients; disruptions (logistics, raw-material shortages, export controls) can interrupt production.
• Operational compliance costs: investments in quality systems, recall reserves, and post-market surveillance can weigh on short-term margins.

• Price and reimbursement risk: public procurement and hospital tender pricing, and National Reimbursement Drug List (NRDL) decisions can materially alter revenue trajectories.
• Concentration risk: if a small number of products or customers account for a large share of sales, adverse events affecting those could disproportionately impact results.
• Foreign competition and substitution: multinational generics and biotech entrants may pressure margins and accelerate commoditization in certain therapy areas.
• Legal and litigation risk: product liability, patent challenges, or antitrust inquiries could result in financial penalties or remediation costs.

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) - Growth Opportunities

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS) is positioned for multi-year growth driven by aging-population demand, strategic collaborations, and an expanding commercial footprint. Key quantified drivers and implications for investors are outlined below.

• Analyst consensus: projected revenue CAGR of 12% over the next five years (2026-2030).
• Market position: estimated 15% share in relevant Chinese pharmaceuticals segments, underpinning pricing power and scale advantages.
• Distribution reach: comprehensive network spanning 30 provinces, improving product accessibility and market penetration.
• R&D and partnership catalysts: 2023 strategic collaboration with a leading biotechnology firm carrying a potential contract value of $100 million to bolster pipeline and technology transfer.
• Balance-sheet signal: total assets rose by 2.92% in Q1 2025, indicating asset-base expansion supporting growth initiatives.

• Revenue sensitivity: at 12% CAGR, revenue roughly doubles in ~6 years, enhancing EBITDA potential if margins are maintained.
• R&D upside: the $100M collaboration can accelerate late-stage assets and licensing opportunities that materially increase long-term top-line and royalty streams.
• Operational leverage: 30-province distribution supports rapid scaling of new products, reducing Go-To-Market cost per unit.
• Balance-sheet flexibility: asset growth (+2.92% in Q1 2025) suggests capacity for capex/R&D spend or selective M&A to supplement organic growth.

For details on the company's guiding principles and long-term aspirations, see: Mission Statement, Vision, & Core Values (2026) of Sichuan Huiyu Pharmaceutical Co., Ltd.